Close menu




April 28th, 2021 | 07:04 CEST

CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!

  • Biotechnology
Photo credits: pixabay.com

The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , CA6936971044 , DE0005664809

Table of contents:


    PsyBio Therapeutics - In pole position

    The topic of magic mushrooms is new only to the stock market. The history of "magic mushrooms" containing psychedelic substances goes back to the Aztec era. But it was not until the late 1950s that psilocybin and psilocin were isolated as the effective substances of the mushroom by the scientist Albert Hofmann, who also discovered LSD. The pharmaceutical Company Sandoz marketed synthetically produced psilocybin under the name Indocybin® for experimental and psychotherapeutic purposes. However, due to its abuse as a narcotic drug, LSD and other psychedelics were banned by the Reagan administration in the early 1970s.

    In recent years, more studies have again been conducted to prove the positive therapeutic effects of drugs such as psilocybin, LSD and other hallucinogens to treat several otherwise untreatable mental disorders such as chronic depression, post-traumatic stress disorder and drug addiction. In this regard, PsyBio Therapeutics is one step ahead of the competition in bringing a revolutionary drug to market.

    In collaboration with the University of Miami's Department of Psychology, the Canadians work with other related compounds, studying their interactions and researching substances that work even better than pure psilocybin. The successful partnership with Miami University, which has already yielded several patents, was expanded last week. The neuropsychiatric drug discovery platform will be expanded to expedite the submission for approval of an investigational new drug, IND, to the FDA.

    Overall, the Canadians see themselves as having a significant advantage over other competitors in research and patent prosecution. The unique selling point that favors PsyBio Therapeutics is a process that can produce psilocybin using bacteria significantly cheaper, faster and more environmentally friendly than any other published method. The Canadians are already a big player in the mental health space and this is demonstrated by recently announced personnel appointments. Bob Oliver, who has more than 25 years of experience in the pharmaceutical industry and has held various senior positions at Otsuka, Wyeth and Johnson & Johnson, is joining the Company, as is Dr. Michael Spigarelli, who has been appointed Chief Medical Officer.

    PsyBio currently has a market capitalization of EUR 14.98 million. The industry is going strong right now. Companies in the same segment already have unicorn status. With its strong patents and successful collaborations, PsyBio Therapeutics could become a significant player in the fight against depression in the long term.

    Evotec - Cooperation expanded

    Good news from Evotec. The collaboration with Bristol Myers Squibb, which started in 2018, has now been extended by the Americans via option. As a result, Evotec will receive a payment of an unknown amount through the early extension. The partnership is ongoing in the field of targeted protein degradation. In addition, the screening is to be expanded and with it, the drug pipeline resulting from the collaboration.

    Evotec Chief Scientific Officer Cord Dohrmann said, "Targeted protein degradation is an emerging new therapeutic modality with high potential to reach not only already validated targets, but also traditionally hard-to-reach targets, through a novel mechanism of action. This will allow first-in-class disease-modifying therapeutics to be explored and developed."

    CureVac - The profiteer from the chaos?

    Missing vaccines in Germany, plus the confusion surrounding AstraZeneca's vaccine. Now comes the next bad news. Since last weekend, the vaccine from BioNTech has also come under criticism. The Israeli Ministry of Health is investigating heart muscle inflammation cases that could be linked to the vaccine administration. The preliminary research mentions "dozens of cases" in which myocarditis has occurred. Myocarditis is an inflammation of the heart muscle, which can have various causes. The disease occurred mainly after the second dose, according to the Israeli coordinator for pandemic control, Nachman Ash.

    The second German vaccine manufacturer, CureVac, is taking a little longer with its research. Now, however, the Tübingen-based Company is in the home stretch. The trial with CureVac's Corona vaccine is nearing completion. Almost all of the 40,000 subjects have been vaccinated twice and the safety and tolerability data look very good, said study leader Peter Kremsner. He expects the vaccine to be licensed and vaccinated soon, he said. "It can happen very quickly now. It should work in June unless something else comes up." It could always happen that the EMA still demands improvements, he said. If there is a vaccine to be added to the portfolio, it's CureVac!


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

    Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

    • Biotechnology

    Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

    Read

    Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

    BrainChip and Palantir with strong rebound - How does BioNTech react?

    • chips
    • Technology
    • Biotechnology

    The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

    Read

    Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

    Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

    • Biotechnology
    • Pharma

    Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

    Read